Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CAD | P27708 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27642519 | 1.00 | ALOX15 (0.41) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL14016339 | 0.86 | ALOX15 (0.48) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL839402 | 0.80 | SLC7A5 (0.54) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL133092 | 0.80 | SLC7A5 (0.54) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL196637 | 0.80 | SLC7A5 (0.54) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL10686184 | 0.78 | ALOX15 (0.41) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL8038311 | 0.78 | ALOX15 (0.41) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| Hydrochloric Acid SCHEMBL133091 | 0.78 | SLC7A5 (0.52) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| SCHEMBL7554622 | 0.78 | CYP2C19 (0.45) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 | |
| Hydrochloric Acid SCHEMBL10887590 | 0.78 | SLC7A5 (0.52) | ALOX15ALDH1A1LMNAHSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-8642799-B2 | Cysteine protease inhibitors for the treatment of parasitic diseases | MERCK CANADA INC. (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2013-09-19 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | MERCK FROSST CANADA LTD. (CA) | 2010-12-02 | — | — | US | disclosed |
| EP-2225196-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | Merck Frosst Canada Ltd. (CA) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009067797-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009067797-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | MERCK FROSST CANADA LTD. (CA) | 2009-06-04 | — | — | WO | disclosed |
| CN-1842515-A | Cathepsin inhibitors | MERCK FROSST CANADA INC (CA) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305056-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASE | CTSL, SERPINB1, CTSZ | ALOX15 853/4885ALDH1A1 1266/4885LMNA 3807/4885 |
| US-20130244962-A1 | CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES | CTSL, SERPINB1, CTSZ | ALOX15 1126/4885ALDH1A1 2383/4885LMNA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.